A carregar...
SWI/SNF aberrations sensitize pancreatic cancer cells to DNA crosslinking agents
While gemcitabine has been the mainstay therapy for advanced pancreatic cancer, newer combination regimens (e.g. FOLFIRINOX) have extended patient survival, though carry greater toxicity. Biomarkers are needed to better stratify patients for appropriate therapy. Previously, we reported that one-thir...
Na minha lista:
| Publicado no: | Oncotarget |
|---|---|
| Main Authors: | , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
Impact Journals LLC
2017
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5839388/ https://ncbi.nlm.nih.gov/pubmed/29515757 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.18632/oncotarget.20033 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|